AbbVie Inc. $ABBV Stock Sold by Hamlin Capital Management LLC

Hamlin Capital Management LLC reduced its position in AbbVie Inc. (NYSE:ABBV) by 1.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 728,805 shares of the company’s stock after selling 9,785 shares during the quarter. AbbVie makes up about 4.6% of Hamlin Capital Management LLC’s investment portfolio, making the stock its 4th largest holding. Hamlin Capital Management LLC’s holdings in AbbVie were worth $190,648,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ABBV. YHB Investment Advisors Inc. boosted its holdings in AbbVie by 0.3% in the 3rd quarter. YHB Investment Advisors Inc. now owns 37,565 shares of the company’s stock worth $9,827,000 after buying an additional 125 shares during the period. Apella Capital LLC lifted its position in shares of AbbVie by 14.2% in the third quarter. Apella Capital LLC now owns 23,477 shares of the company’s stock valued at $6,371,000 after acquiring an additional 2,912 shares in the last quarter. Everhart Financial Group Inc. grew its position in shares of AbbVie by 1.8% during the third quarter. Everhart Financial Group Inc. now owns 25,782 shares of the company’s stock worth $6,744,000 after purchasing an additional 454 shares in the last quarter. Gradient Investments LLC raised its stake in AbbVie by 2.1% during the 3rd quarter. Gradient Investments LLC now owns 79,282 shares of the company’s stock valued at $20,739,000 after purchasing an additional 1,634 shares during the period. Finally, Avidian Wealth Enterprises LLC boosted its stake in AbbVie by 2.5% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 36,207 shares of the company’s stock worth $9,471,000 after purchasing an additional 876 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

ABBV stock traded down $1.75 during midday trading on Thursday, reaching $269.61. 1,794,189 shares of the company traded hands, compared to its average volume of 6,410,183. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $274.94. The business has a 50 day moving average of $258.27 and a 200-day moving average of $235.87. The firm has a market capitalization of $476.34 billion, a price-to-earnings ratio of 76.27, a P/E/G ratio of 1.22 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts anticipate that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ABBV has been the topic of several research analyst reports. Wells Fargo & Company boosted their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Morgan Stanley lifted their target price on AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday. Argus raised their price target on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. JPMorgan Chase & Co. upped their price objective on AbbVie from $280.00 to $285.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Finally, Bank of America reiterated a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $276.11.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen the oncology pipeline. The FDA granted two Breakthrough Therapy Designations for investigational telisotuzumab adizutecan (Temab-A/ABBV-400) in colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory discussions for the company’s next-generation antibody-drug conjugate. AbbVie Temab-A FDA breakthrough designations
• Positive Sentiment: Epkinly produced a significant Phase 3 result. AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The data could support broader adoption and a stronger competitive position against Roche’s Polivy. AbbVie and Genmab Epkinly Phase 3 results
• Positive Sentiment: Analysts remain constructive. Cantor Fitzgerald raised its AbbVie price target to $290 from $285 and maintained an overweight rating. HSBC has also outlined a bullish case with a $315 target, providing additional support for investor sentiment.
• Neutral Sentiment: Broader market factors may be limiting gains. Rising Treasury yields and uncertain equity-market conditions are creating pressure across stocks, even as healthcare companies benefit from defensive characteristics.
• Negative Sentiment: Dividend sustainability remains a concern. Recent commentary highlighted AbbVie’s reported payout ratio near 190%, raising questions about how comfortably earnings cover the dividend. The concern may weigh on income-focused investors, although adjusted earnings and cash flow can differ from reported net income.
• Negative Sentiment: Valuation leaves less room for disappointment. With ABBV trading near its 52-week high and at an elevated earnings multiple, investors may be taking profits or demanding stronger evidence that new medicines can offset long-term Humira-related pressures.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.